• Characterisation of true relapse rates in different geographic areas in the age group mainly affected.

• Assessment of efficacy and safety of short course, high dose primaquine treatment regimens.

• Development of robust point-of-care G6PD diagnostics.

• Investigation of the safety and efficacy of tafenoquine, a long acting 8 aminoquinoline.

• Defining the pharmacokinetic profile of primaquine in at risk populations.

• Confirmation of primaquine efficacy when combined with different blood schizontocidal partner drugs.

• Confirmation of effectiveness of primaquine regimens in clinical practice.

• Quantification of risk of clinically significant haemolysis according to primaquine dose and host susceptibility.

• Development of techniques to distinguish between relapse, reinfection and recrudescent infections.